Back

Cohort study of fever neonates with confirmed community infection of SARS-CoV-2 Omicron: A study Protocol

Li, J.; He, W.; Qi, Y.; Meng, Y.; Peng, X.; Hei, M.

2022-12-29 pediatrics
10.1101/2022.12.28.22283987 medRxiv
Show abstract

IntroductionReports on neonatal coronavirus disease (COVID) have been focused on vertical transmission. There was little information on prevalence of neonates with COVID till up to 18 months of age. It is well known that breastfeeding is beneficial for the growth and development of infants. We hypothesized that breastfeeding will be beneficial for a better prevalence of neonatal COVID. The objective of this study is to explore the prognosis of fever neonates with confirmed community infection of SARS-CoV-2 Omicron, and to clarify whether human milk breastfeeding is beneficial for reducing the rate of severe SARS-CoV-2 Omicron infection in neonates. Methods and analysisThis is a prospective single centre cohort study. Study period is from December, 2022 to December 2024. Inclusion criteria are: (1) Age [≤] 28 days or corrected age [≤] 44 weeks. (2) Fever. (3) Both tests (throat swab) of nucleic acid and antigen of SARS-CoV-2 Omicron were positive. (4) Parents signed the consents. Exclusion criteria is confirmed brain malformations. Patients will be classified into breastfeeding, mixed feeding, and formula feeding groups. The estimate sample size will be 200. The throat swab of infants will be collected for SARS-CoV-2 omicron nucleic acid ad antigen examination. Neonatal COIVD patients will be treated in the Out-Patient Department or admitted to Neonatal Intensive Care Unit according to the severity of infection. All patients will be followed at 3/6/12/18M of age. The endpoint to study was at 18 months of age. Data will be collected by Case Record Form and Electronic Data Capture from the History of In-hospital System. The primary outcome was the rate of severe SARS-CoV-2 infection. SPSS 20.0 software will used for statistical analysis. Ethics and disseminationIt is approved by local Institute of Ethics Review Board (#[2022]-E-240-Y). RegistrationIt is registered in the Chinese Clinical Trail Registry (http://www.chictr.org.cn) (ChiCTR2200067148) Strengths and limitations of this studyO_LIThis is a prospective single centre cohort study for fever neonates with confirmed community infection of SARS-CoV-2 Omicron. C_LIO_LIPatients are categorized into breastfeeding group, mixed feeding group, and formula group. C_LIO_LIThe primary outcome is rate of severe SARS-CoV-2 infection. C_LIO_LIThe secondary outcomes include in-hospital outcomes and follow-up outcomes at 3M/6M/12//18M. C_LIO_LILimitation are the observational nature and the single centre data. C_LI

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.